Transformative change means rethinking the scientific computing workflow.

Building an effective computing environment early on helps ensure positive research outcomes later.

Research scientists have the super-human power of supercomputers to help their teams get ahead of the next outbreak and gain an edge not only for their company’s profit, but also for their own survival.

While there’s no doubt, the realities of much of what transpired in 2020 presented challenges not yet seen or felt by many in my generation and younger, they also fueled a new type of perseverance; one where even the slightest glimmer of silver was enough to line our conscience and tell us to push forward through the tribulations, no matter how hard they seemed.

Drug research and development is one of the most complex processes in today’s world.

Not only must researchers gain familiarity with complex scientific equipment, but they must also optimize their entire laboratory infrastructure to make successful discoveries. Naturally, they must rely on IT technologies and support to do this.

On December 8, 2020, IBM announced what amounts to the death of CentOS, a long-running project that released freely available versions of Red Hat Enterprise Linux (RHEL).

Whether conducting scientific research or market research, the efficiency of your data infrastructure is key. It will either give you a leading competitive edge or become an expensive production bottleneck. Certified AWS engineers bring critical expertise to research workflows and data architecture.

Research labs equipped with the right tools and dashboards will have greater success in meeting drug discovery goals.

Why narrowly-focused manufacturer support can’t offer a holistic view of your lab’s research goals.

To say 2020 has been a year unlike any other so far would be an understatement. COVID-19 has caused the tragic loss of more than 200,000 lives and left permanent scars on many of those fortunate enough to recover from significant disease.

High-performance computing is a powerful weapon in the fight to find treatments and cures for all kinds of diseases.

Essential Questions To Ask When Evaluating Your...

Biotech and pharmaceutical organizations are at the forefront of some of the world’s biggest problems. From developing pest-resistant crops, creating new biofuels, and treating deadly diseases, the march of scientific advancement enables the march of social and civic progress.

AI training is  driving HPC advances in drug...

The climate in which R&D teams are operating today is competitive, to say the least. 

The breakneck pace at which innovation must move in its earliest of stages creates a battleground within the research landscape, one where data is the best weapon against the invisible enemies science aims to destroy, and technology provides the differentiating high-ground from which the fight can be won. 

The sprint toward early discovery is one of the most important legs in the long, expensive, and compliance-driven relay race to bring new drugs or treatments to market. Not only does being first to market with medical innovation provide companies with the opportunity to patent and sell a new treatment as the sole distributor, the reputational value associated with doing so can also be almost immeasurable.